DDInter477 DDInter537
Daptomycin is a cyclic lipopeptide antibacterial agent with a broad spectrum of activity against Gram-positive bacteria, including methicillin-susceptible and -resistant _Staphylococcus aureus_ (MSSA/MRSA) and vancomycin-resistant Enterococci (VRE).[A231379, A231384, L32534] Chemically, daptomycin comprises 13 amino acids, including several non-standard and D-amino acids, with the C-terminal 10 amino acids forming an ester-linked ring and the N-terminal tryptophan covalently bonded to decanoic acid.[A231374, L32534] Daptomycin was first discovered in the early 1980s by researchers at Eli Lilly in soil samples from Mount Ararat in Turkey. Early work on developing daptomycin was abandoned due to observed myopathy but was resumed in 1997 when Cubist Pharmaceuticals Inc. licensed d
Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first line therapy for acute and chronic pain and inflammation from a variety of causes. Diclofenac was the product of rational drug design based on the structures of [phenylbutazone], [mefenamic acid], and [indomethacin]. The addition of two chlorine groups in the ortho position of the phenyl ring locks the ring in maximal torsion which appears to be related to increased potency. It is often used in combination with [misoprostol] to prevent NSAID-induced gastric ulcers. Diclofenac was first approved by the FDA in July 1988 under the trade name Voltaren, marketed by Novartis (previously Ciba-Geigy).
Diclofenac {u} (Compound) resembles {v} (Compound) Clonidine
Diclofenac {u} (Compound) resembles {v} (Compound) Nepafenac
Diclofenac {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bromfenac
Diclofenac {u} (Compound) binds {v} (Gene) ALOX5
Diclofenac {u} (Compound) palliates {v} (Disease) systemic scleroderma
Diclofenac {u} (Compound) is included by {v} (Pharmacologic Class) Nonsteroidal Anti-inflammatory Compounds
Diclofenac {u} (Compound) downregulates {v} (Gene) PUF60
Diclofenac {u} (Compound) causes {v} (Side Effect) Corneal disorder
Diclofenac {u} may cause a minor interaction that can limit clinical effects when taken with {v} Colestipol
Diclofenac {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cholestyramine
Diclofenac (Compound) resembles Clonidine (Compound)
Diclofenac (Compound) resembles Nepafenac (Compound)
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Bromfenac
Diclofenac (Compound) binds ALOX5 (Gene)
Diclofenac (Compound) palliates systemic scleroderma (Disease)
Diclofenac (Compound) is included by Nonsteroidal Anti-inflammatory Compounds (Pharmacologic Class)
Diclofenac (Compound) downregulates PUF60 (Gene)
Diclofenac (Compound) causes Corneal disorder (Side Effect)
Diclofenac may cause a minor interaction that can limit clinical effects when taken with Colestipol
Diclofenac may cause a minor interaction that can limit clinical effects when taken with Cholestyramine